DrugDashboards

Fluocinonide

Fluocinonide · FLUOCINONIDE .5 mg/g · Ointment · Topical · Sun Pharmaceutical Industries, Inc.

NDC 51672-1264-03 · 1 TUBE in 1 CARTON / 60 g in 1 TUBE · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 44% in a year, to $0.1895 per gram — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.1895per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.7529per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$0.6300per unitnegotiated price across 5,435 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$25.16per package of 60GMGolden State Medical Supply, Inc. · Oct 3, 2025

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.6300per unit
middle half $0.4263$1.10 · 5,435 plans · Apr 1, 2026
Est. net of rebates
≈ $0.6300
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
99%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 90%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00Nov 2013Sep 2026$0.1895
155 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$38.86
Reported to Texas DSHS · 2026 annual filing · Taro

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$460,835
15,174 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

15Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 43% year over year+15

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for fluocinonide (other) in the next 90 days

3 Class I/II recall(s) in 12 months · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA075008
TE code
AB
Approval date
Jun 30, 1999
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class III · TerminatedSep 20, 2017
    Taro Pharmaceuticals U.S.A., Inc.Cross contamination with other products: traces of Dapsone were found in the finished product.
  • Class III · TerminatedMar 17, 2017
    Taro Pharmaceuticals U.S.A., Inc.Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.

Manufacturers of Fluocinonide (Ointment)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackFLUOCINONIDE .05 mg/gJul 15, 2026Sep 3, 2026
NuCare Pharmaceuticals,Inc.FLUOCINONIDE .5 mg/gJul 15, 2026Sep 2, 2026
Preferred Pharmaceuticals Inc.FLUOCINONIDE .5 mg/gJul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.FLUOCINONIDE .5 mg/gJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.FLUOCINONIDE .5 mg/gJul 15, 2026Sep 2, 2026
Xiromed LLCFLUOCINONIDE .05 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fluocinonide — NDC 51672-1264-03," retrieved September 3, 2026, https://drugdashboards.com/drug/51672126403.

Free to cite with attribution — see how the data is put together.